NASDAQ : PYXS
Pyxis Oncology, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.89 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 225.77M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 216.22M |
| Enterprise Value | 201.05M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 119.46M |
| Shares Outstanding | 119.46M |
| Shares Change (YoY) | +3.27% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 4.20% |
| Owned by Institutions (%) | 14.57% |
| Float | 71.07M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.59 |
| Forward PS | 11,122.19 |
| PB Ratio | 10.04 |
| P/TBV Ratio | 18.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 18.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.34 |
| Quick Ratio | 1.20 |
| Debt / Equity | 1.56 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -179.10% |
| Return on Assets (ROA) | -62.95% |
| Return on Invested Capital (ROIC) | -82.23% |
| Return on Capital Employed (ROCE) | -326.84% |
| Weighted Average Cost of Capital (WACC) | 10.93% |
| Revenue Per Employee | $197,107 |
| Profits Per Employee | -$1.58M |
| Employee Count | 56 |
| Asset Turnover | 0.12 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.10M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.38 |
| 52-Week Price Change | -45.32% |
| 50-Day Moving Average | 2.66 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 38.41 |
| Average Volume (20 Days) | 905,164 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.35M |
| Short Previous Month | 4.89M |
| Short % of Shares Out | 3.64% |
| Short % of Float | 6.12% |
| Short Ratio (days to cover) | 3.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 11.04M |
| Gross Profit | 8.65M |
| Operating Income | -89.71M |
| Pretax Income | -87.62M |
| Net Income | -88.73M |
| EBITDA | -85.53M |
| EBIT | -89.71M |
| Loss Per Share | -$1.40 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 33.00M |
| Total Debt | 17.83M |
| Net Cash | 15.16M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 11.44M |
| Book Value Per Share | 0.18 |
| Working Capital | 9.26M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -67.91M |
| Capital Expenditures | -9,000 |
| Depreciation & Amortization | 4.18M |
| Net Borrowing | n/a |
| Free Cash Flow | -67.92M |
| FCF Per Share | -$0.57 |
Margins
| Measure | Value |
|---|
| Gross Margin | 78.37% |
| Operating Margin | -812.74% |
| Pretax Margin | -793.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.27% |
| Shareholder Yield | -3.27% |
| Earnings Yield | -77.51% |
| FCF Yield | -31.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.88 |
| Price Target Difference | 390.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | -3.96% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -15.71 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |